Dopamine-acetylcholine interactions in the rat striatum in vivo microdialysis studies by Boer, Peter de
  
 University of Groningen
Dopamine-acetylcholine interactions in the rat striatum in vivo microdialysis studies
Boer, Peter de
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
1992
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Boer, P. D. (1992). Dopamine-acetylcholine interactions in the rat striatum in vivo microdialysis studies. s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
SUMMARY
The observation that both anticholinergics and dopamine agonists ameliorate
parkinsonian s;,.rnptoms has generated a great number of neurochemical studies
aimed to establish an interaction between these two transmitter systems. From
these studies it was concluded that dopamine inhibits the output of acetylcholine
in the striatum via a dopamine D2 receptor. Furthermore, the increases in the
output ofacetylcholine or the decreases in the tissue content ofacetylcholine after
systemic administration of dopamine receptor blockers indicated that dopamine
tonically inhibited striatal cholinergic neurons. Before the development of a brain
microdialysis method for the measurement of acetylcholine, the studies on the
dopamine-acetylcholine interactions in the striatum were done using in vitro
release studies, tissue measurements or using push-pull cannulas in gallamine
immobilized cats. Since brain microdialysis provides a unique opportunity to
measure neurochemical events in freely moving, conscious animals, the striatal
dopamine-acetylcholine interactions were investigated using this method.
Initially we failed to show an interaction between nigrostriatal dopaminergic
fibers and cholinergic interneurons using brain microdialysis. Since these Íindings
were largely at variance with the prevailing view in the scientific community, we
decided to study some methodological aspects pertaining to microdialysis studies
to validate the method and to provide further evidence that would either confirm
or deny the existence of a striatal dopamine-aceQrlcholine interaction.
In the introduction the role of acelrlcholine and dopamine in basal ganglia
functioning is discussed. Both dopamine and acetylcholine are thought to be
important in the gating of information that is largely derived from the cortex
flowing through the striatal cell mosaic to the basal ganglia output centers.
Furthermore, the possibility that dopamine and acetylcholine interactions occur via
a common target neuron is discussed in the light of electrophysiological and
anatomical evidence. It is concluded that there might be a convergence of
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that electrophysiological data not clearly show an antagonistic interaction of the
transmitters dopamine and acetylcholine.
In chapter I we discuss the effect of neostigmine (a acet5rlcholinesterase
inhibitor), coinfused in our artiÍicial CSF, on muscarinic autoreceptor responses.
It is shown that 0.1 ptmoVl neostigmine increases the extracellular levels of
acetylcholine about ten-fold and that the increase in extracellular acet;rlcholine
results in the attenuation of the effect of the muscarinic agonist oxotremorine and
a potentiation of the effect of the muscarinic antagonist atropine.
In chapter 2 the muscarinic autoreceptor that modulates the output of
acetylcholine from the striatum is further characterized by infusing the selective
muscarinic antagonists 4-DAMP, AF-DX 116 and pirenzepine. It is shown that 4-
DAMP increases the output of acetSzlcholine from the striatum most potently,
followed by pirenzepine and AF-DX 116 respectively. From these observations we
conclude that an Mr-muscarinic autoreceptor modulates the overflow of
ace[rlcholine from the striatum.
In chapter 3 the effect of the calcium concentration of the microdialysis
perfusion fluid is tested both on autoreceptor and heteroreceptor responses of
cholinergic and dopaminergic neurons. Whereas the output of acetylcholine was
unresponsive to D2 receptor activation at elevated perfusion fluid calcium
concentrations (3.4 mmol/l), at more physiological calcium concentrations (1.2
mmoVl) an inhibition of the output of acetylcholine could be measured after D2
receptor stimulation. It is shown that the attenuation of the effect of dopamine
agonists can be attributed to muscarinic autoreceptor occupation at 3.4 mmol/l
calcium. Infusion of the dopamine receptor antagonist (-)-sulpiride did not affect
the output of acetylcholine either at 1.2 mmoVl or 3.4 mmol/l calcium. The
muscarinie agonist oxotremorine also decreased the output of acetylcholine at 1.2
mmoVl calcium but not at 3.4 mmoVl calcium. The output of striatal dopamine
could be increased after infusion of the dopamine antagonist (-)-sulpiride and
decreased after infusion of the dopamine agonist (-)-N-0437 both at 1.2 mmoVl and
3.4 mmoVl calcium present in the perfusion fluid. Neither oxotremorine, nor
atropine could affect the output of striatal dopamine at both calcium
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concentrations. The percentual increase in the output of dopamine after infusion
of the dopamine releasing drug (+)-amphetamine or the dopamine uptake inhibitor
nomifensine was greater at 1.2 mmol/l than at 3.4 mmol/l calcium.
These studies indicate that the output of acetylcholine is modulated by muscarinic
autoreceptors and dopaminergic (D2) heteroreceptors. The D2 receptors are
probably not tonically activated. The output of striatal dopamine is modulated by
dopamine (D2) autoreceptors but not by muscarinic heteroreceptors.
Whereas in chapter 3 the drugs were infused into the striatum, in chapter 4
the results of systemic applications of dopamine agonists and antagonists are
studied on the release of acegrlcholine. The dopamine agonists apomorphine and
N-0437 decrease the output of striatal acetylcholine, whereas the dopamine
antagonists sulpiride and haloperidol increase the output ofstriatal acetylcholine.
In chapter 5 the effects of dopamine D1 and D2 receptor ligands, the
dopamine releaser (+)-amphetamine and the dopamine uptake inhibitor
nomifensine are studied on the release of striatal acetylcholine as a function of the
post-implantation interval of a microdialysis probe. It is shown that striatal
dopamine D2 but not Dl receptors are involved in the modulation of striatal
acef'lcholine release. The dopamine D2 receptors are not occupied 16-24 h aÍter
probe implantation, but a tonic interaction between dopaminergic and cholinergic
systems can be seen 40-48 h after probe implantation. The dopamine releasing
drug (+)-amphetamine and the dopamine uptake inhibitor nomifensine dose-
dependently increase the output of striatal dopamine. However, only when the
extracellular dopamine levels are more than sevenfold increased, the output of
striatal acetylcholine is affected. These studies confirm the existence of a dopamine
D2 receptor mediated inhibition of the release of acetylcholine and the existence
of a tonic inhibition of the cholinergic interneuron in the striatum by dopamine.
Furthermore, the importance of the post-implantation of a microdialysis probe for
the pharmacological responsiveness of striatal cholinergic neurons is shown.
The theme of chapter 6 might be clinically relevant. Patients with Parkinson's
disease are currently treated with L-DOPA, an ergot drug of a combination of these
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striatal acetylcholine was assumed to be similar. However, in this study we show
that the output of acetylcholine from the striatum is increased after systemic
application of L-DOPA. In contrast, the output of striatal acetylcholine decreases
after systemic injections of bromocriptine. These effects are not only seen in
animals with an intact nigrostriatal dopaminergic system, but also in animals
treated with the dopaminergic neurotoxin 6-hydroxydopamine. It is speculated that
the increased output of striatal acetylcholine is the result of the stimulation of
extrastriatal dopamine Dl receptors. This topic is further discussed in the
discussion.
Not only dopaminergic systems modulate the output of acetSrlcholine from the
striatum. In chapter 7 we show that in addition GABA-ergic receptor activation
by direct acting receptor ligands modulates the output of striatal acet;rlcholine.
Striatal acetylcholine release may be tonically inhibited via a GABAo-receptor.
Since intrastriatal infusion of dopamine Dl agonists that increase the output of
GABA does not affect the output of acetylcholine, we conclude that the GABA-ergic
modulation of striatal cholinergic neurons occurs via GABA-ergic cell elements in
the striatum that have no D1 receptors.
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